The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2017

Filed:

Oct. 25, 2013
Applicant:

The Children's Hospital of Philadelphia, Philadelphia, PA (US);

Inventors:

Robert J. Levy, Merion Station, PA (US);

Michael Chorny, Huntingdon Valley, PA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 2/00 (2006.01); C07K 4/00 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 14/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01); A01N 43/02 (2006.01); A61K 31/335 (2006.01); A61B 17/52 (2006.01); A61N 2/00 (2006.01); A61K 47/48 (2006.01); A61K 9/00 (2006.01); A61K 41/00 (2006.01); A61K 31/337 (2006.01); A61N 2/02 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48238 (2013.01); A61K 9/0009 (2013.01); A61K 31/337 (2013.01); A61K 41/00 (2013.01); A61K 47/4893 (2013.01); A61K 47/48861 (2013.01); A61K 47/48915 (2013.01); A61N 2/002 (2013.01); A61N 2/02 (2013.01);
Abstract

A therapeutic particle comprises a particle comprising one or more therapeutic agents and one or more fibrin-avid peptide variants attached to the surface of the particle. A method for magnetically targeting a therapeutic agent toward a device in a subject, such as a temporarily introduced magnetizable catheter or an implanted stent, comprises administering the therapeutic particles to the subject and generating a magnetic field, which targets the magnetic particles toward the device. The affinity peptide-modified therapeutic particles may comprise an effective amount of an anti-proliferative agent, such as paclitaxel, to inhibit or prevent in-stent restenosis.


Find Patent Forward Citations

Loading…